2,6-二甲基哌嗪 | 108-49-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 哌嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 2,6-二甲基哌嗪
• 中文别名: 顺-2,6-二甲基胡椒嗪；顺式-2,6-二甲基哌嗪；顺-2,6-二甲基哌嗪
• 英文名称: 3,5-dimethylpiperazine
• 英文别名: 2,6-Dimethylpiperazin；2,6-dimethylpiperazine
• CAS: 108-49-6
• 化学式: C₆H₁₄N₂
• mdl: MFCD00005956
• 分子量: 114.191
• InChiKey: IFNWESYYDINUHV-UHFFFAOYSA-N

物化性质

• 熔点：
  108-111 °C (lit.)
• 沸点：
  162 °C (lit.)
• 密度：
  0.9140 (estimate)
• 闪点：
  113 °F
• 溶解度：
  氯仿（微溶）、甲醇（微溶）
• 稳定性/保质期：
  避免与光、氧化物和水分直接接触。

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险等级：
  4.1
• 危险品标志：
  F,Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38,R11
• WGK Germany：
  3
• 海关编码：
  2933599090
• 危险品运输编号：
  UN 1325 4.1/PG 2
• 危险类别：
  4.1
• 包装等级：
  III
• 危险标志：
  GHS02,GHS07
• 危险性描述：
  H228,H315,H319,H335
• 危险性防范说明：
  P210,P261,P305 + P351 + P338
• 储存条件：
  储存于阴凉、通风的库房。远离火种、热源及水源，包装需密封，避免与空气接触。应与氧化剂分开存放，切忌混储。使用防爆型照明和通风设施，并禁止使用易产生火花的机械设备和工具。储区内应备有泄漏应急处理设备和合适的收容材料。

SDS

Name:	2 6-Dimethylpiperazine 97% cis Material Safety Data Sheet
Synonym:
CAS:	108-49-6

Section 1 - Chemical Product MSDS Name:2 6-Dimethylpiperazine 97% cis Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
108-49-6	2,6-Dimethylpiperazine	97%	203-588-9

Hazard Symbols: XI F
Risk Phrases: 11 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Highly flammable. Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. Will burn if involved in a fire. This material in sufficient quantity and reduced particle size is capable of creating a dust explosion. Flammable solid.
Extinguishing Media:
Use water spray to cool fire-exposed containers. Use water fog, dry chemical, carbon dioxide or alcohol type foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Remove all sources of ignition. Use a spark-proof tool.

---

Section 7 - HANDLING and STORAGE
Handling:
Use spark-proof tools and explosion proof equipment. Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Keep away from sources of ignition. Store in a cool, dry place.
Store in a tightly closed container. Flammables-area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 108-49-6: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystalline powder
Color: ochre
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 162 deg C @ 760.0
Freezing/Melting Point: 106-111 deg C
Autoignition Temperature: Not available.
Flash Point: 44 deg C ( 111.20 deg F)
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water: Slightly soluble.
Specific Gravity/Density:
Molecular Formula: C6H14N2
Molecular Weight: 114.19

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, light, ignition sources, exposure to moist air or water.
Incompatibilities with Other Materials:
Strong oxidizing agents, strong acids.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 108-49-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2,6-Dimethylpiperazine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION
Other No information available.

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: FLAMMABLE SOLID, ORGANIC, N.O.S.*
Hazard Class: 4.1
UN Number: 1325
Packing Group: II
IMO
Shipping Name: FLAMMABLE SOLID, ORGANIC, N.O.S.
Hazard Class: 4.1
UN Number: 1325
Packing Group: II
RID/ADR
Shipping Name: FLAMMABLE SOLID, ORGANIC, N.O.S.
Hazard Class: 4.1
UN Number: 1325
Packing group: II

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI F
Risk Phrases:
R 11 Highly flammable.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 16 Keep away from sources of ignition - No
smoking.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 33 Take precautionary measures against static
discharges.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 108-49-6: No information available.
Canada
CAS# 108-49-6 is listed on Canada's NDSL List.
CAS# 108-49-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 108-49-6 is listed on the TSCA inventory.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

化学性质：淡黄色片状结晶。

用途：主要用作医药中间体，广泛应用于合成氟喹诺酮类药物中的斯帕沙星。

反应信息

• 作为反应物：
  描述：

  2,6-二甲基哌嗪 在 Cp*Ir(6,6'-dionato-2,2'-bipyridine)(H₂O) 作用下， 以 对二甲苯 为溶剂， 反应 20.0h， 以29%的产率得到2,6-二甲基吡嗪
  参考文献：
  名称：

  铱催化加氢/脱氢可实现2,5-二甲基吡嗪和2,5-二甲基哌嗪之间的可逆转化，从而有效地储氢

  摘要：

  已经开发出一种基于氮杂环化合物氢化和脱氢的新型储氢系统，该系统使用一种铱催化剂。通过该新系统，与以前的系统相比，使用相对少量的溶剂进行了高效的氢存储。2,5-二甲基吡嗪和2,5-二甲基哌嗪之间的可逆转化，伴随着三当量氢的吸收和释放，几乎可以定量重复至少四次，而不会降低效率。此外，还实现了在无溶剂条件下的氢存储。

  DOI：

  10.1002/anie.201705452
• 作为产物：
  描述：

  2,6-二甲基-1,4-二亚硝基-哌嗪 在 盐酸 、 氨基磺酸铵 作用下， 生成 2,6-二甲基哌嗪
  参考文献：
  名称：

  Alicyclic nitrosamines and nitrosamino acids as transnitrosating agents

  摘要：

  DOI：

  10.1021/jo01312a022
• 作为试剂：
  描述：

  1-(4-chlorophenyl)-2-(1,3-dithietan-2-ylidene)-2-pyridin-4-ylethanone 、 2,6-二甲基哌嗪 、 肼 在 甲苯 、 2,6-二甲基哌嗪 、 四氢呋喃 、 乙酸乙酯 、 ammonium hydroxide 作用下， 以 甲苯 、 四氢呋喃 为溶剂， 反应 29.0h， 以1.6 g of 2-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3,5-dimethylpiperazine as a white solid (43% overall yield), mp: 236-238° C的产率得到2-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3,5-dimethylpiperazine
  参考文献：
  名称：

  Substituted pyrazoles as p38 kinase inhibitors

  摘要：

  本文描述了一类吡唑衍生物，可用于治疗p38激酶介导的疾病。特别感兴趣的化合物由公式（IA）定义，其中R1、R2、R3和R4如规范中所述。

  公开号：

  US06979686B1

文献信息

• Dual Pharmacophores - PDE4-Muscarinic Antagonistics
  申请人：Callahan James Francis

  公开号：US20090197871A1

  公开（公告）日：2009-08-06

  The present invention is directed to novel compounds of Formula (I), pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of/and or prophylaxis of respiratory diseases, including antiinflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

  本发明涉及式(I)的新化合物，药物组合物及其在治疗中的应用，例如作为磷酸二酯酶IV (PDE4)的抑制剂和毒蕈碱乙酰胆碱受体 (mAChRs)的拮抗剂，用于治疗和/或预防呼吸道疾病，包括抗炎症和/或过敏性疾病，如慢性阻塞性肺病 (COPD)、哮喘、鼻炎 (例如过敏性鼻炎)、特应性皮炎或银屑病。
• [EN] DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS<br/>[FR] PHARMACOPHORES DUALS, ANTAGONISTES DES RÉCEPTEURS MUSCARINIQUES ET INHIBITEURS DE L'ACTIVITÉ PDE4
  申请人：GLAXO GROUP LTD

  公开号：WO2009100169A1

  公开（公告）日：2009-08-13

  The present invention is directed to novel compounds of Formula's (I) - (VI), and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of and/or prophylaxis of respiratory diseases, including inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

  本发明涉及式(I) - (VI)的新化合物，以及其药学上可接受的盐、药物组合物及其在治疗中的应用，例如作为磷酸二酯酶IV (PDE4)的抑制剂和肌碱乙酰胆碱受体 (mAChRs)的拮抗剂，用于治疗和/或预防呼吸道疾病，包括炎症性和/或过敏性疾病，如慢性阻塞性肺病（COPD）、哮喘、鼻炎（例如过敏性鼻炎）、特应性皮炎或银屑病。
• [EN] BIS-HETEROARYL DERIVATIVES AS MODULATORS OF PROTEIN AGGREGATION<br/>[FR] DÉRIVÉS BIS-HÉTÉROARYLIQUES EN TANT QUE MODULATEURS DE L'AGRÉGATION DES PROTÉINES
  申请人：NEUROPORE THERAPIES INC

  公开号：WO2017020010A1

  公开（公告）日：2017-02-02

  The present invention relates to certain bis-heteroaryl compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto- temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer including melanoma.

  本发明涉及某些双杂环芳基化合物，含有它们的药物组合物，以及使用它们的方法，包括用于预防、逆转、减缓或抑制蛋白聚集的方法，以及治疗与蛋白聚集相关的疾病的方法，包括帕金森病、阿尔茨海默病、路易体病、帕金森病伴痴呆、额颞型痴呆、亨廷顿病、肌萎缩侧索硬化和多系统萎缩等神经退行性疾病，以及包括黑色素瘤在内的癌症。
• Structure−Activity Relationships of the Quinolone Antibacterials against Mycobacteria:  Effect of Structural Changes at N-1 and C-7
  作者：Thomas E. Renau、Joseph P. Sanchez、Jeffrey W. Gage、Julie A. Dever、Martin A. Shapiro、Stephen J. Gracheck、John M. Domagala

  DOI：10.1021/jm9507082

  日期：1996.1.1

  smegmatis as well as Gram-negative and Gram-positive bacteria. The activity of the compounds against M. fortuitum was used as a barometer of M. tuberculosis activity. The results demonstrate that (i) the activity against mycobacteria was related more to antibacterial activity than to changes in the lipophilicity of the compounds, (ii) the antimycobacterial activity imparted by the N-1 substituent was in the

  对常规药物治疗有抵抗力的结核感染的再次出现表明需要针对结核分枝杆菌的替代化学疗法。作为优化针对结核分枝杆菌的喹诺酮类抗菌药物研究的一部分，我们准备了一系列N-1-和C-7取代的喹诺酮类化合物，以研究这两个位置上喹诺酮类修饰物与活性之间的特定结构-活性关系。对抗分枝杆菌。通过文献方法合成的化合物被评估了对福分枝杆菌和耻垢分枝杆菌以及革兰氏阴性和革兰氏阳性细菌的活性。化合物对堡垒分枝杆菌的活性用作结核分枝杆菌活性的晴雨表。
• [EN] COMPOUNDS THAT INHIBIT MCL-1 PROTEIN<br/>[FR] COMPOSÉS INHIBANT LA PROTÉINE MCL-1
  申请人：AMGEN INC

  公开号：WO2018183418A1

  公开（公告）日：2018-10-04

  Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (I), or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

  本文提供了髓样细胞白血病1蛋白（Mcl-1）抑制剂，其制备方法，相关的药物组合物，以及使用这些物质的方法。例如，本文提供了化合物的化学式（I）或其立体异构体；以及这些化合物的药用盐和含有这些化合物的药物组合物。本文提供的化合物和组合物可以用于治疗癌症等疾病或症状。

表征谱图